Rahul Bhargava, Director and Head of Hematology, Hematocology, and Stem Cell Transplant at Fortis Health Care, shared a post on LinkedIn about a paper he co-authored with colleagues published in Hemoglobin:
“Bone Marrow Transplant: A Decade of Hope for Sickle Cell Patients – the largest series from India
Local solution for a global problem.
Bone marrow transplant (BMT) remains the only curative modality for millions of patients suffering from sickle cell disease. This paper stands as a testament to scientific discovery, perseverance, and clinical excellence.
A decade-long journey has firmly established BMT as a safe and effective treatment, especially in the hands of a trained and experienced team led by Dr Vikas Dua. It offers patients and families renewed confidence that BMT—when performed at the right time, in the right place, by the right team – can transform the lives of lifelong sicklers.
It is truly a win–win for everyone involved. While our ultimate goal remains to prevent sickle cell disease from being passed on to future generations, until that day arrives, BMT will continue to provide hope, confidence, and a real chance at a cure for those affected.
May this milestone inspire continued efforts toward a future free of sickle cell disease.
Congrats to all the authors for this remarkable work and dedication.”
Title: Encouraging Outcomes of Hematopoietic Stem Cell Transplantation in Pediatric Sickle Cell Disease- A Decade-Long Experience from the Developing World
Authors: Swati Bhayana, Sohini Chakaroborty, Shrinidhi Nathany, Arun Danewa, Sunisha Arora, Parminder Pal Singh, Surbhi Pokhriyal, Nikhil Kumar, Anusha Swaminathan, Neha Rastogi Panda, Madhur Arora, Rahul Bhargava, and Vikas Dua
You can read the Full Article in Hemoglobin.
More posts featuring Rahul Bhargava.
